FTY720 promotes pulmonary fibrosis when administered during the remodelling phase following a bleomycin-induced lung injury.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pulmonary Pharmacology & Therapeutics

• Publication date

  2017-06-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.pupt.2017.03.010PMID 28323056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of Idiopathic Pulmonary Fibrosis.

  2016cited by this paper
• Treatment with a sphingosine analog after the inception of house dust mite-induced airway inflammation alleviates key features of experimental asthma

  2015cited by this paper
• Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.

  2014cited by this paper
• FTY720, a Sphingosine-1 Phosphate Receptor Modulator, Improves Liver Fibrosis in a Mouse Model by Impairing the Motility of Bone Marrow-Derived Mesenchymal Stem Cells

  2014cited by this paper
• Life-threatening asthma attack during prolonged fingolimod treatment: case report

  2014cited by this paper
• Respiratory disease and respiratory physiology: Putting lung function into perspective interstitial lung disease

  2014cited by this paper
• Fingolimod-induced asthma deterioration in a patient with relapsing–remitting multiple sclerosis

  2014cited by this paper
• Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages.

  2014cited by this paper
• FTY720 attenuates paraquat-induced lung injury in mice.

  2014cited by this paper
• A review of current and novel therapies for idiopathic pulmonary fibrosis.

  2013cited by this paper
• Sphingosine 1-Phosphate (S1P) Receptor Agonists Mediate Pro-fibrotic Responses in Normal Human Lung Fibroblasts via S1P2 and S1P3 Receptors and Smad-independent Signaling

  2013cited by this paper
• FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease

  2013cited by this paper
• Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases.

  2013cited by this paper
• New Disease-Modifying Therapies and New Challenges for MS

  2012cited by this paper
• Bleomycin induced lung fibrosis increases work of breathing in the mouse.

  2012cited by this paper
• Molecular and cellular mechanisms of pulmonary fibrosis

  2012cited by this paper
• Integrating mechanisms of pulmonary fibrosis

  2011cited by this paper
• Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF).

  2011cited by this paper
• Modulation of Chemokines and Allergic Airway Inflammation by Selective Local Sphingosine-1-phosphate Receptor 1 Agonism in Lungs

  2011cited by this paper
• Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice.

  2011cited by this paper
• The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice.

  2011cited by this paper
• Phosphorylation of the Immunomodulator FTY720 Inhibits Programmed Cell Death of Fibroblasts Via the S1P3 Receptor Subtype and Bcl-2 Activation

  2010cited by this paper
• Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.

  2010cited by this paper
• Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis.

  2010cited by this paper
• Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

  2009cited by this paper
• Synthetic Analogs of FTY720 [2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] Differentially Regulate Pulmonary Vascular Permeability in Vivo and in Vitro

  2009cited by this paper
• Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor‐β‐induced mouse fibrosis

  2008cited by this paper
• Local Not Systemic Modulation of Dendritic Cell S1P Receptors in Lung Blunts Virus-Specific Immune Responses to Influenza

  2008cited by this paper
• The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

  2008cited by this paper
• Essential Requirement for Sphingosine Kinase 2 in a Sphingolipid Apoptosis Pathway Activated by FTY720 Analogues*

  2007cited by this paper
• Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.

  2007cited by this paper
• Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses

  2006cited by this paper
• Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.

  2006cited by this paper
• The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells

  2006cited by this paper
• TGF‐β signaling and the fibrotic response

  2004cited by this paper
• Nonsteroidal Anti-Inflammatory Drug Reduces Neutrophil and Macrophage Accumulation but Does Not Improve Tendon Regeneration

  2003cited by this paper
• Time course of bleomycin‐induced lung fibrosis

  2002cited by this paper

• Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions

  2025cites this paper
• Effects of sphingolipid metabolism related genes-SPTLC1, ORMDL3, SPHK1 and S1PR3 polymorphisms on susceptibility to hashimoto’s thyroiditis

  2025cites this paper
• Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway

  2023cites this paper
• Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing

  2023cites this paper
• The Role of Sphingolipids in Regulating Vascular Permeability in Idiopathic Pulmonary Fibrosis

  2023cites this paper
• Peimine Alleviated Bleomycin-Induced Pulmonary Fibrosis in Mice Through Reducing Epithelial-Mesenchymal Transition, Inflammation and Oxidative Stress and Regulating Host Metabolism

  2023cites this paper
• S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung

  2022cites this paper
• Deletion of sphingosine kinase 2 attenuates cigarette smoke-mediated chronic obstructive pulmonary disease-like symptoms by reducing lung inflammation

  2022cites this paper
• Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage

  2021cites this paper
• Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension

  2021cites this paper
• Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-β.

  2021cites this paper
• Pulmonary toxicants and fibrosis: innate and adaptive immune mechanisms.

  2020cites this paper
• A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models

  2019cites this paper
• DDDT_A_185418 2873..2886

  2019cites this paper
• Total extract of Xin Jia Xuan Bai Cheng Qi decoction inhibits pulmonary fibrosis via the TGF-β/Smad signaling pathways in vivo and in vitro

  2019cites this paper
• Diablo: A Double-Edged Sword in Cancer?

  2018cites this paper
• Effects of formaldehyde exposure on the development of pulmonary fibrosis induced by bleomycin in mice

  2018cites this paper